Roberta and the Brazil team distil 18 months of post-RDC 751 launches into a single hour. Includes case-study walkthroughs and a printable rejection-reason cheat sheet.
Taevas
UpcomingPharmaceuticals
Brazil Pharma Annual Update — RDC 751/2022 in Practice and 2026 Pricing Realities
A São Paulo-led briefing on what it actually takes to launch and price a pharmaceutical product in Brazil today — ANVISA dossier expectations, CMED pricing pathways, post-launch SUS dynamics, and the most common rejection reasons in 2026.
13 August 20261h2 time zones
Reserve your seat
Register to attend live
Recording shared with all registrants 24h after the live session
Save your spot for the live room.
One-click registration — calendar invites land in your inbox the moment you sign up.
Register nowWhat you'll learn
Four big things you walk away with
Practical, no-fluff takeaways you can act on the same week.
ANVISA RDC 751/2022 risk classes and which apply to your portfolio
How a Brazilian legal representative differs from a distributor — and why you need both
Customs realities for medical, pharma, and consumer-health imports into Brazil
Cost and timeline benchmarks for fresh-registration vs grandfathering
Agenda
How the 60-minute session runs
Tight, well-rehearsed, and always ends on time.
- 00:00 – 03:00
Welcome and housekeeping
Introductions, attendee map, audio check.
- 03:00 – 12:00
Market context and the regulator lens
Snapshot of growth drivers, recent regulatory shifts, and what changed in the past 12 months.
- 12:00 – 30:00
Step-by-step: licence pathway walk-through
Live walk-through of the documents, dossiers, and decision points an entering brand will face.
- 30:00 – 42:00
Operational realities post-approval
Vigilance, renewals, port clearance, recall procedures, change-control.
- 42:00 – 55:00
Live Q&A
Open-floor questions answered by the speaker.
- 55:00 – 60:00
Closing and next steps
How to book a 1:1 follow-up consultation and access the slide deck.
Hosted by
Meet the speaker
Roberta Maria Rodrigues
Head of Brazil OperationsBrazil
Roberta runs Taevas' São Paulo office and is an ANVISA-listed legal representative. She has secured RDC 751/2022 registrations for over 80 international device families and authored Taevas' Brazil cosmetic notification playbook.
Connect on LinkedInRelated sessions
More from the same series
Upcoming
45 min
Jun
11
2026
EU MDR — What's Changed in 2026 and Why It Matters for Non-EU Brands
A focused 45-minute briefing on the 2026 EU MDR amendments — extended Article 120 transitional periods, the digital UDI pilot, and how Authorised Representative obligations have shifted. Aimed at non-EU brands holding (or seeking) CE marking.
4 takeaways6-step agenda2 zones
Michael Lambell
EU Pharma Lead · United Kingdom
Medical DevicesPharmaceuticals
RegisterUpcoming
1h
May
14
2026
Mexico Beauty & Personal Care Market Entry — COFEPRIS Sanitary Notification Workshop
Live workshop walk-through of Mexico's notificación sanitaria pathway for cosmetics and personal-care products. Format requirements, label compliance, and the cost-and-timeline reality of going to market through Sephora MX, Amazon MX, and modern trade.
4 takeaways6-step agenda2 zones
Mario Duque
LATAM Director · Mexico & Colombia
Personal Care & BeautyPharmaceuticals
RegisterOn-demand
1h
Apr
10
2025
India Market Entry Simplified: Authorized Agent Services for Global Brands (Spanish)
Conducted in Spanish. Unlock key insights for entering India's market via the Authorized Agent / IAR pathway — regulations, licensing, consumer trends, and the role of an IAR in ensuring compliance. Spanish-language session by special request from the LATAM cohort.
4 takeaways6-step agenda2 zonesIn Spanish
Ishita Singh
Director · Global Market Entry · India HQ
Medical DevicesPharmaceuticals+2
Watch session